StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
37
Publishing Date
2023 - 09 - 12
1
2023 - 09 - 07
1
2023 - 07 - 05
1
2023 - 06 - 26
1
2023 - 05 - 04
1
2023 - 02 - 15
1
2023 - 02 - 12
1
2022 - 11 - 29
1
2022 - 10 - 17
1
2022 - 10 - 06
1
2022 - 09 - 26
1
2022 - 08 - 31
2
2022 - 08 - 03
1
2022 - 06 - 14
1
2022 - 06 - 03
1
2022 - 05 - 17
1
2022 - 03 - 31
1
2021 - 12 - 07
1
2021 - 12 - 05
1
2021 - 11 - 12
1
2021 - 11 - 01
1
2021 - 10 - 27
2
2021 - 09 - 02
1
2021 - 07 - 23
1
2021 - 07 - 06
1
2021 - 06 - 04
1
2021 - 04 - 20
1
2021 - 03 - 25
1
2021 - 03 - 08
1
2021 - 03 - 02
2
2021 - 03 - 01
1
2021 - 02 - 09
1
2021 - 01 - 27
1
2021 - 01 - 26
1
Sector
Communications
1
Health technology
37
Tags
Anti-cd40
1
Antibody
6
Australia
1
Back
2
Biotech-beach
5
Brazil
1
Breakthrough therapy
1
Canada
1
Cancer
7
China
2
Chronic pain
1
Clearance
4
Clinical-trials-phase-ii
2
Collaboration
1
Covid
10
Covid-19
7
Designation
3
Drop
1
Enroll
3
Fast track designation
2
Fda
6
Fda clearance
3
Fibromyalgia
1
Global
1
Gloperba
1
Granted
2
Infections
1
License
7
Lung
1
Lung cancer
3
Market
1
Migraine
1
N/a
29
Opioid
1
Osteoarthritis
4
Phase 1
3
Phase 1b
4
Phase 2
8
Phase 2b
4
Phase 3
2
Positive
9
Positive results
2
Potential
1
Regulatory
1
Research
3
Respiratory
1
Results
9
Sars-cov-2
1
Sp-103
3
Sti-1558
5
Study
5
Syndros
1
Therapeutics
4
Therapy
1
Topline
1
Treatment
37
Trial
10
Trial results
1
Trials
1
Ztlido
3
Entities
3m company
21
Abbott laboratories
61
Abbvie inc.
121
Accuray incorporated
21
Adamis pharmaceuticals corporation
19
Adial pharmaceuticals, inc
22
Alnylam pharmaceuticals, inc.
38
Amgen inc.
47
Arcutis biotherapeutics, inc.
25
Arrowhead pharmaceuticals, inc.
21
Astellas pharma inc
51
Astrazeneca plc
52
Bausch health companies inc.
36
Biogen inc.
42
Biohaven pharmaceutical holding company ltd.
19
Bioxcel therapeutics, inc.
20
Boston scientific corporation
21
Brainsway ltd.
41
Bridgebio pharma, inc.
20
Bristol-myers squibb company
94
Cns pharmaceuticals, inc.
26
Coherus biosciences, inc.
28
Compass pathways plc
20
Ecolab inc.
47
Eli lilly and company
180
Fortress biotech, inc.
27
Gilead sciences, inc.
50
Glaxosmithkline plc
103
Hoth therapeutics, inc.
24
Incyte corporation
77
Intellia therapeutics, inc.
32
Jazz pharmaceuticals plc
20
Johnson & johnson
209
Karyopharm therapeutics inc.
33
Koninklijke philips n.v.
21
Medicinova, inc.
24
Medtronic plc
46
Merck & company, inc.
66
Moleculin biotech, inc.
28
Novartis ag
144
Novo nordisk a/s
37
Nrx pharmaceuticals inc
20
Orange
87
Perrigo company
22
Pfizer, inc.
74
Reata pharmaceuticals, inc.
28
Regeneron pharmaceuticals, inc.
57
Regenxbio inc.
25
Sanofi
295
Sorrento therapeutics, inc.
37
Takeda pharmaceutical company limited
54
Teleflex incorporated
21
Teva pharmaceutical industries ltd
79
Tg therapeutics, inc.
24
Tonix pharmaceuticals holding corp.
32
Ultragenyx pharmaceutical inc.
25
Verrica pharmaceuticals inc.
23
Vertex pharmaceuticals incorporated
27
Viatris inc.
46
Xylem inc.
35
Symbols
FNCTF
1
SCLX
2
SRNE
37
TEVA
1
Exchanges
Nasdaq
37
Nyse
1
Crawled Date
2023 - 09 - 12
1
2023 - 09 - 07
1
2023 - 07 - 05
1
2023 - 06 - 26
1
2023 - 05 - 04
1
2023 - 02 - 15
1
2023 - 02 - 13
1
2022 - 11 - 29
1
2022 - 10 - 17
1
2022 - 10 - 06
1
2022 - 09 - 26
1
2022 - 08 - 31
2
2022 - 08 - 03
1
2022 - 06 - 14
1
2022 - 06 - 03
1
2022 - 05 - 17
1
2022 - 03 - 31
1
2021 - 12 - 07
1
2021 - 12 - 05
1
2021 - 11 - 12
1
2021 - 11 - 01
1
2021 - 10 - 27
2
2021 - 09 - 02
1
2021 - 07 - 23
1
2021 - 07 - 06
1
2021 - 06 - 04
1
2021 - 04 - 20
1
2021 - 03 - 25
1
2021 - 03 - 08
1
2021 - 03 - 02
2
2021 - 03 - 01
1
2021 - 02 - 09
1
2021 - 01 - 27
2
Crawled Time
00:00
1
01:00
2
04:00
2
08:00
1
13:00
4
13:20
3
13:30
1
14:00
4
14:04
2
15:00
2
15:20
2
16:00
3
18:00
2
19:00
3
20:00
2
20:20
1
21:00
1
21:04
1
Source
www.biospace.com
8
www.globenewswire.com
28
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
entities :
Sorrento therapeutics, inc.
save search
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Published:
2023-09-12
(Crawled : 13:30)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-90.48%
|
O:
-3.62%
H:
7.95%
C:
-8.1%
covid-19
treatment
trial
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published:
2023-09-07
(Crawled : 13:00)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-86.97%
|
O:
0.52%
H:
42.58%
C:
36.03%
osteoarthritis
positive
treatment
trial
therapeutics
results
Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study
Published:
2023-07-05
(Crawled : 13:00)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-94.33%
|
O:
5.1%
H:
1.02%
C:
-0.27%
positive
treatment
results
study
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
Published:
2023-06-26
(Crawled : 13:20)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-94.23%
|
O:
3.9%
H:
0.0%
C:
-3.06%
sti-1558
covid-19
treatment
trial
Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain
Published:
2023-05-04
(Crawled : 13:00)
- globenewswire.com
SCLX
|
$0.8812
-2.09%
-2.13%
2.1M
|
|
-83.64%
|
O:
0.0%
H:
4.91%
C:
-4.36%
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-91.7%
|
O:
-0.46%
H:
2.92%
C:
-0.5%
sp-103
ztlido
back
treatment
study
Sciatica Treatment Market to Reach USD 991.3 Million, Globally, by 2031 at 3.9% CAGR: Allied Market Research
Published:
2023-02-15
(Crawled : 16:00)
- prnewswire.com
TEVA
|
$12.86
0.63%
0.0%
10M
|
Health Technology
|
25.46%
|
O:
-0.98%
H:
1.58%
C:
1.58%
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-89.87%
|
O:
1.27%
H:
2.75%
C:
-17.4%
treatment
research
market
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
Published:
2023-02-12
(Crawled : 00:00)
- globenewswire.com
SCLX
|
$0.8812
-2.09%
-2.13%
2.1M
|
|
-90.63%
|
O:
-20.92%
H:
10.39%
C:
-6.84%
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-97.87%
|
O:
-35.61%
H:
9.04%
C:
-57.51%
treatment
canada
migraine
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Published:
2022-11-29
(Crawled : 20:00)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-98.4%
|
O:
1.6%
H:
3.54%
C:
2.36%
sti-1558
covid-19
treatment
australia
topline
china
positive
study
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster
Published:
2022-10-17
(Crawled : 13:00)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-98.51%
|
O:
4.48%
H:
11.43%
C:
9.29%
sti-1558
covid-19
treatment
trials
global
study
Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on “New Horizons for the Treatment of Non-small Cell Lung Cancer”
Published:
2022-10-06
(Crawled : 13:20)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-98.76%
|
O:
-1.24%
H:
3.46%
C:
-1.89%
treatment
lung
therapeutics
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published:
2022-09-26
(Crawled : 14:00)
- biospace.com/
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-98.71%
|
O:
-0.65%
H:
5.19%
C:
-1.95%
treatment
osteoarthritis
trial
therapeutics
phase 2
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute LBP
Published:
2022-08-31
(Crawled : 08:00)
- biospace.com/
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-98.97%
|
O:
5.15%
H:
2.94%
C:
0.49%
sp-103
ztlido
treatment
fda
designation
granted
fast track designation
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)
Published:
2022-08-31
(Crawled : 04:00)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-98.97%
|
O:
5.15%
H:
2.94%
C:
0.49%
sp-103
ztlido
treatment
fda
designation
back
granted
fast track designation
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
Published:
2022-08-03
(Crawled : 13:20)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-99.23%
|
O:
0.77%
H:
8.32%
C:
2.3%
sti-1558
covid-19
treatment
study
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
Published:
2022-06-14
(Crawled : 15:00)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-98.56%
|
O:
2.16%
H:
1.41%
C:
-0.7%
gloperba
treatment
license
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
Published:
2022-06-03
(Crawled : 15:20)
- biospace.com/
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-98.74%
|
O:
8.18%
H:
2.33%
C:
-0.58%
sti-1558
covid-19
treatment
therapeutics
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Published:
2022-05-17
(Crawled : 15:20)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-98.61%
|
O:
4.17%
H:
6.0%
C:
4.67%
treatment
license
trial
cancer
enroll
antibody
Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
Published:
2022-03-31
(Crawled : 14:00)
- biospace.com/
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-99.16%
|
O:
1.27%
H:
0.26%
C:
-2.92%
covid-19
treatment
fda
clearance
phase 2
Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)
Published:
2021-12-07
(Crawled : 19:00)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-99.66%
|
O:
-1.68%
H:
9.4%
C:
7.52%
treatment
phase 2
xin
osteoarthritis
trial
enroll
Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron
Published:
2021-12-05
(Crawled : 20:20)
- globenewswire.com
SRNE
|
$0.024
-8.85%
57K
|
Health Technology
|
-99.64%
|
O:
-9.22%
H:
0.0%
C:
0.0%
treatment
covid
potential
sars-cov-2
infections
← Previous
1
2
Next →
Gainers vs Losers
67%
33%
Top 10 Gainers
KUKE
|
$2.88
2.49%
7.64%
360K
|
CXM
4
|
$11.34
-0.44%
4.27%
1.7M
|
Information
RNR
4
|
$224.74
0.85%
3.52%
310K
|
Finance
BSBR
|
$5.25
2.54%
0.38%
430K
|
Finance
DV
|
News
|
$29.43
-2.36%
0.24%
1.9M
|
Information
JOE
4
|
$54.88
1.22%
0.22%
210K
|
Finance
MUSA
4
|
$417.23
1.06%
0.01%
170K
|
Retail Trade
JBI
4
|
$15.14
1.34%
0.0%
2.9M
|
SBS
|
$15.49
-1.59%
-0.84%
4.6M
|
Utilities
ML
4
|
$69.13
-4.48%
-1.64%
110K
|
Your saved searches
Save your searches and get alerts when important news are released.